🎉 M&A multiples are live!
Check it out!

Anixa Biosciences Valuation Multiples

Discover revenue and EBITDA valuation multiples for Anixa Biosciences and similar public comparables like Benevolent AI, Pharming, and Vivoryon Therapeutics.

Anixa Biosciences Overview

About Anixa Biosciences

Anixa Biosciences Inc a cancer-focused biotechnology company, develops vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.


Founded

1982

HQ

United States of America
Employees

5

Website

anixa.com

Financials

LTM Revenue n/a

LTM EBITDA n/a

EV

$68.3M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Anixa Biosciences Financials

Anixa Biosciences has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Anixa Biosciences achieved revenue of n/a and an EBITDA of -$13.8M.

Anixa Biosciences expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Anixa Biosciences valuation multiples based on analyst estimates

Anixa Biosciences P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $0.2M n/a XXX XXX XXX
Gross Profit n/a $49K XXX XXX XXX
Gross Margin 0% Infinity% XXX XXX XXX
EBITDA -$11.0M -$13.8M XXX XXX XXX
EBITDA Margin -5221% -Infinity% XXX XXX XXX
Net Profit -$13.6M -$9.8M XXX XXX XXX
Net Margin -6474% -Infinity% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Anixa Biosciences Stock Performance

As of April 15, 2025, Anixa Biosciences's stock price is $3.

Anixa Biosciences has current market cap of $85.3M, and EV of $68.3M.

See Anixa Biosciences trading valuation data

Anixa Biosciences Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$68.3M $85.3M XXX XXX XXX XXX $-0.38

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Anixa Biosciences Valuation Multiples

As of April 15, 2025, Anixa Biosciences has market cap of $85.3M and EV of $68.3M.

Anixa Biosciences's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Anixa Biosciences's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Anixa Biosciences and 10K+ public comps

Anixa Biosciences Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $68.3M XXX XXX XXX
EV/Revenue n/a XXX XXX XXX
EV/EBITDA n/a XXX XXX XXX
P/E -6.7x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF n/a XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Anixa Biosciences Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Anixa Biosciences Valuation Multiples

Anixa Biosciences's NTM/LTM revenue growth is n/a

Anixa Biosciences's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $2.8M for the same period.

Over next 12 months, Anixa Biosciences's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Anixa Biosciences's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Anixa Biosciences and other 10K+ public comps

Anixa Biosciences Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth -100% XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth 26% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee $2.8M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue n/a XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Anixa Biosciences Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Vaccines & Immunotherapies comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Anixa Biosciences M&A and Investment Activity

Anixa Biosciences acquired  XXX companies to date.

Last acquisition by Anixa Biosciences was  XXXXXXXX, XXXXX XXXXX XXXXXX . Anixa Biosciences acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Anixa Biosciences

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Anixa Biosciences

When was Anixa Biosciences founded? Anixa Biosciences was founded in 1982.
Where is Anixa Biosciences headquartered? Anixa Biosciences is headquartered in United States of America.
How many employees does Anixa Biosciences have? As of today, Anixa Biosciences has 5 employees.
Who is the CEO of Anixa Biosciences? Anixa Biosciences's CEO is Dr. Amit Kumar,PhD.
Is Anixa Biosciences publicy listed? Yes, Anixa Biosciences is a public company listed on NAS.
What is the stock symbol of Anixa Biosciences? Anixa Biosciences trades under ANIX ticker.
When did Anixa Biosciences go public? Anixa Biosciences went public in 1989.
Who are competitors of Anixa Biosciences? Similar companies to Anixa Biosciences include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Anixa Biosciences? Anixa Biosciences's current market cap is $85.3M
Is Anixa Biosciences profitable? Yes, Anixa Biosciences is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.